Related Experiment Video
Updated: Jun 23, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Tinea capitis in early infancy treated with itraconazole: a pilot study
1Department of Dermatology, Medical University of Graz, Graz, Austria. barbara.binder@klinikum-graz.at
Itraconazole effectively treated Microsporum canis tinea capitis in infants. This study found itraconazole (given at 5mg/kg daily) to be safe and well-tolerated in this young population.
Area of Science:
- Dermatology
- Pediatric Mycology
- Pharmacology
Background:
- Tinea capitis, a common childhood scalp fungal infection, is rare in infants under one year.
- Microsporum canis is a frequent cause of tinea capitis.
Purpose of the Study:
- To assess the efficacy, tolerability, and safety of itraconazole for treating tinea capitis in infants.
- To evaluate itraconazole's use in children aged 3 to 46 weeks caused by Microsporum canis.
Main Methods:
- A prospective case note study was conducted.
- Diagnostic methods included KOH testing and fungal cultivation on Sabouraud dextrose agar.
- Treatment involved daily itraconazole at 5mg/kg for 3-6 weeks.
Main Results:
- Seven infants (5 female, 2 male) diagnosed with Microsporum canis tinea capitis were treated.
- All patients received itraconazole without reported side effects.
- Clinical and mycological cure was achieved in all participants.
Conclusions:
- Itraconazole is a safe and effective treatment for Microsporum canis-induced tinea capitis in infants.
- The study supports itraconazole's use in the first year of life for this condition.
Related Concept Videos
Cryptococcal Meningitis
Candidiasis
Antifungal Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Antiprotozoal Agents
